Patent intelligence Β· WO
WO 2023156493
FORMES CRISTALLINES DE NALTREXONE
FORMES CRISTALLINES DE NALTREXONE
Patent details β WO 2023156493
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Aug 24, 2023
- Expiration
- Aug 19, 2043
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- CPC classes
- A61K 31/ 485 A I, A61P 25/ 32 A I, A61P 25/ 36 A I, A61P/2532
Quick answer
WO 2023156493 (FORMES CRISTALLINES DE NALTREXONE) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted Aug 24, 2023. Expires Aug 19, 2043 (17 years remaining) β relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- Grant date
- Expiration
- Claims
- β
- CPC classes
- A61K 31/ 485 A I, A61P 25/ 32 A I, A61P 25/ 36 A I, A61P/2532, A61P/2536
More from ALKERMES PHARMA IRELAND LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022263543
Pharmaceutical compositions comprising sorbitan esters
granted -
US 2023302008
METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE
granted -
WO 2023154894
COMPOSITIONS ET PROCΓDΓS D'IMMUNOTHΓRAPIE ANTICANCΓREUSE
granted -
CY 2022006
Ξ Ξ‘ΞΞ¦ΞΞ‘ΞΞΞΞ Ξ¦ΞΞ₯ΞΞΞ‘ΞΞΩΠΞΞΞ΀ΩΠΞΞΠΠΧΑΞΣΠ΀ΞΞ₯Ξ£ Σ΀ΞΞ ΞΞΞ©ΞΞ Ξ ΞΞΞΞΞΩΠΞΞΣΩΞ
granted -
US 2022354866
IMMEDIATE RELEASE MULTILAYER TABLET
granted -
CA 3172871
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted -
CA 3172874
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted
Frequently asked questions
What is US patent 2023156493?
WO 2023156493 (FORMES CRISTALLINES DE NALTREXONE) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted Aug 24, 2023. Expires Aug 19, 2043 (17 years remaining) β relevant for patent-cliff and LOE planning.
Who owns WO 2023156493?
ALKERMES PHARMA IRELAND LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2023156493 expire?
Our index shows an expiration date of Aug 19, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.